HPV Vaccination: Understanding the Impact on HPV Disease

Human papillomavirus (HPV) infection is the cause of several types of cancers, genital warts, and recurrent respiratory papillomatosis. HPV is one of the most common sexually transmitted infections, with more than 70% of sexually active men and women being infected at least once in their lifetime^1-3. Persistent infection over several years with oncogenic HPV types increases the probability of cancer development

Dowload PDF

Key Points:

• Human papillomavirus (HPV) is one of the most common sexually transmitted infections.
• Oncogenic, high risk HPV types 16 and 18 are associated with approximately 70% of all cervical cancers. Oncogenic HPV types 31, 33, 35, 45, 52 and 58 account for an additional 20% of cervical cancers. Infection with oncogenic HPV types is also associated with cancers of the anus, oropharynx, penis, vagina and vulva.
• Non-oncogenic, low risk HPV types 6 and 11 are responsible for 90% of anogenital warts.
• Two HPV vaccines are licensed for use in Canada, Cervarix^TM (GlaxoSmithKline) and Gardasil® (Merck). While both vaccines provide protection against HPV types 16 and 18, Gardasil also protects against HPV types 6 and 11.
• Clinical trials have demonstrated both HPV vaccines to be highly efficacious (95% - 100% vaccine efficacy) against precancerous cervical lesions. However, the vaccines’ long-term protectiveness is unknown at this time.
• The majority of HPV vaccine associated adverse events reported in Canada have been pain at the injection site.
• All provinces and territories in Canada have implemented publicly-funded HPV vaccination programs. However, reported HPV vaccine uptake varies across the country, ranging from around 50% in Alberta and Manitoba to approximately 85% in Newfoundland, Nova Scotia and Quebec.
• Although the HPV vaccine has the potential to play a significant role in reducing the incidence of cervical cancer, the HPV vaccine is type specific for only 70% of cervical cancers and not all girls will receive the vaccine, thus resources to maintain the availability and access to Pap tests must remain.

Extension of the public HPV vaccination program to males is under consideration in the provinces of Prince Edward Island, New Brunswick, and Quebec.

• NCCID Projects

  Explore Our Body of Work

• Publications

  View our Online Publicaation Archive

• Facts & Figures

  Stats, Guidelines & Research in our Project Areas

• Infectious Disease News

  The Latest National and International News